Coronary Artery Disease and Pregnancy by Titia P.E. Ruys et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
5 
Coronary Artery Disease and Pregnancy 
Titia P.E. Ruys1, Mark R. Johnson2 and Jolien W. Roos-Hesselink1  
1Department of Cardiology, Thorax centre, Erasmus Medical Centre, Rotterdam, 
2Academic Department of Obstetrics and Gynaecology, Imperial College London, 
Chelsea and Westminster Hospital, London, 
1The Netherlands 
2UK 
1. Introduction  
Although an acute coronary syndrome (ACS) in women of childbearing age is rare, 
consequences are considerable, especially in pregnant women. In this chapter we will give 
an overview of the current literature regarding pregnancy and ACS. Acute coronary 
syndrome prior to pregnancy, acute coronary syndrome in the antepartum, peripartum and 
post partum period and heart failure during pregnancy will be described using patient 
cases, followed by an overview of literature and recommendations. Epidemiology, 
pathophysiology, counselling, use of medication, treatment possibilities, delivery, maternal 
and fetal outcome will be discussed. 
2. Epidemiology 
Acute coronary syndrome is rare in women of childbearing age (16 to 45 years of age). 
During these years pregnancy has shown to increase the risk of ACS three- to fourfold. 
(James et al., 2006) Between 1991-2000 the overall incidence of pregnancy related acute 
coronary syndrome was reported 2,7 per 100.000 deliveries. (Ladner et al., 2005) A decade 
later James published on risk factors of ACS during pregnancy in a population based study 
in the United States, he reported an incidence of 6,2 per 100.000 deliveries between 2000-
2002. (James et al., 2006) The higher incidence can be explained by three causes: First of all 
with the improved diagnostic tests, especially troponin assessment, more women with acute 
chest pain have been diagnosed with ACS; secondly, an increase of known cardiovascular 
risk factors is seen in the pregnant population; and finally, maternal age increased in the 
western world. (Ventura., 2004) 
Cardiovascular risk factors specific for ACS during pregnancy are very similar to the risk 
factors of non-pregnant patients. The main risk factors for ACS in women are smoking, lipid 
metabolism disorders, hypertension and diabetes. But in pregnant patients also thrombophilia 
and anaemia are risk factors for ACS. In the last decades lifestyle has changed in the western 
world. (Ogden et al., 2006) As a consequence of high calorie intake and little exercise the 
incidence of obesity and diabetes has increased drastically. (Cecchine et al., 2010)  
In addition to cardiovascular risk factors, a few obstetric risk factors have been discovered. The 
most important being multiparity, but also a history of preeclampsia, post-partum 
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haemorrhage, transfusions and post-partum infections are risk factors for ACS during 
pregnancy. (Ladner et al., 2005) In addition, obstetric complications may elevate the risk of 
developing ACS later in life. Still birth, preeclampsia and recurrent miscarriage are a risk 
factor for ACS later in life in the general population. Endothelial dysfunction is hypothesised 
to be the link between hypertension in the pregnancy and cardiovascular disease later in life. 
(Pina, 2011) 
Maternal age is one of the most important risk factor for ACS during pregnancy. Over the 
age of 30 women have an odds ratio of 9.5. This is even higher in women over 40, with an 
odds ratio of 31.6. (James et al., 2006) There is a continuing trend of childbearing at older 
ages, caused by carrier choices of highly educated women. The advances in reproductive 
technology enable many older women to conceive, leading to more women with a high risk 
for ACS during pregnancy. Therefore it may be expected that the incidence of ACS during 
pregnancy will increase further in the coming years.  
3. Changes during pregnancy  
Knowledge of the normal physiological changes during pregnancy, labour and the 
postpartum period is essential for doctors looking after pregnant women with heart disease. 
In the following section we will give an overview of the most important physiological 
changes in pregnancy. 
The majority of the cardiovascular changes occur in the first twenty weeks of gestation. The 
first hemodynamic change is a decline in total peripheral vascular resistance (TPVR) of 40-
70%. The decline in TPVR is a response to circulating gestational hormones. The drop in 
TPVR results in a relatively underfilled vascular state reflected by a fall in blood pressure. 
The blood volume increases with 1-1,5 litre (30-50%) as a response to the low blood 
pressure. The increase in plasma volume is relatively higher than the increase in red blood 
cells resulting in a physiological haemodilution. The combined changes result in a fifty 
percent increase in circulating blood volume during pregnancy. (Robson et al., 1989) 
Cardiac afterload decreases with the fall in TPVR and cardiac preload increases with the rise 
of blood volume. These changes result in an increase in cardiac output of 30-50% from the 
20th week of gestation as shown in figure 1. During pregnancy heart rate increases by 10-20 
beats per minute, this mainly happens in the third trimester. Pregnancy is associated with 
changes in cardiac structure secondary to the increase in cardiac output, with left ventricular 
dimensions increasing from between 10-30%; ejection fraction and fractional shortening also 
increase. (Hunter & Robson, 1992) 
The vascular system changes with the increase in stroke volume. Arterial stiffness decreases 
during the first trimester, but slightly rises from the second trimester and vascular 
distensibility is increased. (Ulusoy et al., 2006) These changes are partially mediated by 
gestational hormones, for example estrogen has favourable effects on the endothelium and 
vascular smooth muscle cells and increases vasodilatation (Mendelsohn & Karas, 1999), but 
progestins reduce estradiol-induced endothelium-mediated vascular relaxation. (Skafar et 
al., 1997) 
Delivery increases the stroke volume by 20%, which contributes to the 25% increase in 
cardiac output. This is initiated by the greater maternal oxygen consumption caused by the 
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increase in uterine contractions in combination with maternal stress and pain, which in turn 
stimulates higher epinephrine levels. 
 
 
 
Fig. 1. Hemodynamic changes in the normal pregnancy: CO cardiac output, SV stroke 
volume, HR heart rate, Hb haemoglobin concentration and TPVR total peripheral vascular 
resistance. Reproduced from: “Karamermer Y, Roos-Hesselink JW. Pregnancy and adult 
congenital heart disease. Expert Rev Cardiovasc Ther 2007; 5: 859-869” with permission of 
Expert Reviews Ltd . 
 
Major hemodynamic changes also occur during the puerperium, (from birth until 6 to 8 
weeks after delivery). Decompression of the inferior cava and the return of uterine blood to 
the circulation (auto-transfusion) cause a period of overfilling. In women with impaired 
cardiac function this may result in cardiac decompensation. All gestational hemodynamic 
changes return to prepregnancy levels 3-12 months after pregnancy.  
Pregnancy is a hypercoagulable state, probably an evolutionary adaptation to reduce the 
risk of severe haemorrhage after labour. There is a decrease in releasable tissue plasminogen 
activator (tPA), an increase in fast-acting tPA inhibitor and an increase in factors V, VII, VIII, 
IX, X, XII and von Willebrand factor. (Fletcher et al., 1979) Protein S is increased throughout 
pregnancy, while increased resistance to activated protein C is only seen during the second 
and third trimesters. (Coolman et al., 2006) The hypercoagulable state is partially reversed 
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by haemodilution and the activation of the fibrinolytic system. During delivery the placenta 
and myometrium release tPA inhibitors further increasing the hypercoagulable state 
(Yoshima et al., 1992); but by around 6 weeks after pregnancy the coagulation and 
fibrinolytic systems return to normal. 
In summary pregnancy is a hypercoagulable state and an increase of 30-50% in cardiac 
output is seen as a result of decrease of vascular resistance and increased blood volume, 
stroke volume and heart rate.  
4. Medication during pregnancy  
The food and drug administration (FDA) made a classification system for the use of drugs in 
pregnant women:  
Category A: Adequate and well-controlled studies have failed to demonstrate a risk to the 
fetus in the first trimester of pregnancy (and there is no evidence of risk in later 
trimesters).  
Category B: Animal reproduction studies have failed to demonstrate a risk to the fetus and 
there are no adequate and well-controlled studies in pregnant women.  
Category C: Animal reproduction studies have shown an adverse effect on the fetus and 
there are no adequate and well-controlled studies in humans, but potential benefits may 
warrant use of the drug in pregnant women despite potential risks.  
Category D: There is positive evidence of human fetal risk based on adverse reaction data 
from investigational or marketing experience or studies in humans, but potential benefits 
may warrant use of the drug in pregnant women despite potential risks.  
Category X: Studies in animals or humans have demonstrated fetal abnormalities and/or 
there is positive evidence of human fetal risk based on adverse reaction data from 
investigational or marketing experience, and the risks involved in use of the drug in 
pregnant women clearly outweigh potential benefits. 
In table 1 an oversight is given on the safety during pregnancy and breast feeding of drugs 
which are commonly prescribed by cardiologist. 
 
Medication Indication FDA Safe 
during 
pregnancy
Extra information Safe 
during 
breast 
feeding 
Extra information 
Atenolol Hypertension, 
Arrhythmias, 
D Yes IUGR and premature 
birth 
No A case report of 
adverse effects 
Other beta 
blockers 
Hypertension, 
Arrhythmias,  
Marfan disease 
ACS 
C Yes Low birth weight, 
hypoglycemia and 
bradycardia in the 
fetus 
Yes Careful 
monitoring of the 
neonatal heart rate 
ACE 
inhibitors  
Hypertension,  
Heart failure 
D No High incidence fetal 
death and fetotoxic 
effect: renal failure, 
renal dysplasia 
Yes Traces are detected 
in breast milk, fetal 
monitoring is 
advisable 
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ARB Hypertension,  
Heart failure 
D No High incidence fetal 
death and fetal anuria 
No data  
Spironolacto
ne 
Hypertension,  
Heart failure 
D No Potential anti-
androgenic effects on 
the developing male 
fetus 
Yes  
Thiazide 
diuretics 
Hypertension,  
Heart failure 
C No Hypovolemia can lead 
to reduced uterine 
perfusion 
Yes May suppress 
lactation 
Loop 
diuretics 
Hypertension,  
Heart failure 
C Yes Hypovolemia can lead 
to reduced uterine 
perfusion 
Yes  
Digoxin Arrhythmias C Yes No reports of 
congenital defects 
Yes Neonatal heart 
rate should be 
monitored after 
delivery 
Nitrates Hypertension, 
Angina  
B Yes Careful titration is 
advised to avoid 
maternal hypotension 
No data  
Calcium 
channel 
antagonists 
Hypertension, 
Preeclampsia 
C Yes Diltiazem: an increase 
in major birth defects 
have been reported 
Yes Excreted in breast 
milk  
Statins  Lipid disorders X No Animal studies 
demonstrated 
increased skeletal 
abnormalities, fetal 
and neonatal mortality
No Probably appears 
in breast milk, 
there are some 
concerns with 
disruption of 
infant lipid 
metabolism 
Aspirin ACS, 
Arrhythmias 
C Yes Low dose aspirin is 
safe 
Yes No adverse effects 
have been reported 
in low dose 
Clopidogrel ACS B No data The benefits of using 
clopidogrel in some 
high risk pregnancies 
may outweigh the 
potential fetal risks 
No  
LMWH and 
UFH 
Arrhythmias 
Diminished 
ventricular 
function 
Thrombosis  
C Yes Factor Xa should by 
measured to monitor 
the therapeutic levels 
of LMWH, which may 
fluctuate during 
pregnancy 
Yes  
Table 1. Medication. ACE: Angiotensin-converting enzyme inhibitors. ARB: Angiotentin 
receptor antagonists. 
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5. Pre-existing coronary disease 
A 39 year old woman was seen at the out patient clinic of a referral hospital for counselling. Three 
month earlier she had suffered a non ST elevation myocardial infarction (NSTEMI). On coronary 
angiogram (CAG) a thrombotic occlusion of an atherosclerotic lesion of the left coronary artery was 
seen and treated with a drug eluting stent. She had never been pregnant, had recently stopped 
smoking, was a non diabetic and normotensive. Her family history did not reveal any cardiovascular 
disease. Her left ventricular function was assessed with echocardiography and the estimated ejection 
fraction was 48%. She was prescribed aspirin, clopidogrel, simvastatine, perindopril and nifedipine.  
5.1 Counselling prior to pregnancy  
Ideally all women of reproductive age with cardiac disease should undergo thorough 
evaluation before becoming pregnant. This evaluation should focus on identifying and 
quantifying risk to the mother and the unborn child. During pre pregnancy counselling life 
expectancy and ethical aspects of parenthood should also be discussed. An exercise test and 
echocardiogram should be performed. Risk stratification is made to inform the patient of 
possible complications during pregnancy. The influence of pregnancy on the cardiac 
condition has to be considered, but also the cardiac condition may influence pregnancy 
outcome, especially the incidence of hypertension, preeclampsia, arrhythmias and 
thrombotic complications may be higher. 
Low dose aspirin, beta blockade and nitrates should be continued during pregnancy. The 
safety of clopidogrel is unknown. In individual cases with recent drug eluting stent 
placement, continuation should be considered. ACE inhibitors and ARBs should be stopped 
in all patients or in the pre-conception clinic or immediately when pregnancy is diagnosed. 
Generally, statins should be stopped, however, in an individual patient with very high 
cholesterol, continuation may be considered. 
5.2 Recurrence rate 
Only limited data on recurrence risks have been published. Badui et al described 18 women 
in the literature with previous ACS, the mothers were 1 or 2 years after ACS and none of 
these patients had a recurrent ACS. (Badui & Enciso, 1996) One of the reasons for this lack of 
data is the fact that many women are advised against pregnancy after ACS. Doctors advise 
against pregnancy for a number of reasons, first it is suggested that the hypercoagulable 
state of pregnancy raises the chance of recurrence of thrombotic obstruction of the coronary 
arteries. Second the increase in left ventricular mass and heart rate lead to a high cardiac 
oxygen demand. The increased cardiac oxygen demand can lead to relative coronary flow 
mismatch in patients with pre-existing coronary artery disease. Finally, fear of complications 
may make them conservative.  
The first patient was advised to wait for at least 3 more months before trying to become pregnant to 
make sure that she was cardiovascularly stable. Before conception perindopril, statin and clopidogrel 
are advised to be discontinued until after delivery. If pregnancy occurred, then the plan was made for 
outpatient review at 6, 12, 20 and 32 weeks of gestation. 
5.3 Impaired left ventricular function 
A 41 year old patient presented to the out patient department of a referral hospital with a desire for 
pregnancy. She had not been pregnant before. One year earlier she had suffered from a STEMI, CAG 
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at that time revealed atherosclerosis and thrombosis of the LAD and she was treated with 
thrombosuction and a drug-eluting stent. Six month after the ACS her left ventricular function was 
measured with echocardiography, ejection fraction was 35 %.  
In 2000 Siu published predictors of cardiac events, mainly heart failure and arrhythmias. 
Prior cardiac events, left ventricular outflow obstruction, NYHA class > II, cyanosis and 
systemic ventricular dysfunction (ejection fraction >40%) were predictor for adverse 
maternal outcome. If one predictor was present, cardiac event rate was 27%. (Siu et al., 2001) 
However, the patient population consisted of patients with congenital or valvular disease 
and a diminished systemic ventricular function was mainly found in patients with 
transposition of the great arteries after atrial repair. To use these results to predict cardiac 
events in ischemic cardiomyopathy patients is at least questionable.  
Generally women are advised against pregnancy if they have a left ventricular dysfunction 
with an ejection fraction under 40% and have a dilated left ventricle. (Prebitero et al., 2009) 
In a study on pregnancy in patients with dilated cardiomyopathy, an OR of 43 was found 
for moderate or severe left ventricular dysfunction and 39% of the pregnancies where 
complicated. (Grewal et al., 2009) Risk factors for adverse events were moderate (EF 30%-
44%) or severe (EF<30%) ventricular dysfunction and NYHA class III or IV at baseline or 
prior cardiac event. Compared with non-pregnant patients with dilated cardiomyopathy, 
pregnant patients needed more medication and adverse cardiac events were more common. 
Pregnancy seemed to have a negative impact on the short-term clinical course for women 
with dilated cardiomyopathy. (Grewal et al., 2010) We need similar data for women with 
ischemic left ventricular dysfunction.  
In case of heart failure during pregnancy diuretics are considered to be first choice, but 
diuretics could result in hypovolemia, leading to reduced uterine perfusion and so should 
be used with caution. Nitrates can be used safely and digoxin can be considered, especially 
if the patients has atrial fibrillation. Such patients should be treated in hospital and bed rest 
is advisable.  
In the study of Grewal et al, the neonatal complication rate was high, especially in women 
with severe dilated cardiomyopathy, suggesting that in the context of severe left ventricular 
dysfunction, the heart may not be able perfuse the utero-placental circulation sufficiently. 
Therefore, regular growth scans to indentify fetal growth restriction and frequent review in 
a combined clinic with an obstetrician and cardiologist is advised. (Signore et al., 2010)  
The second patient was informed about the high maternal and fetal risks associated with pregnancy in 
women with impaired left ventricular function as well as the lack of information on the recurrence 
rates of ACS during pregnancy. She decided not to take the risk. 
5.4 Delivery 
Planning delivery should be done in a multidisciplinary team consisting of an obstetrician, 
anaesthesiologist and cardiologist. The patient should be informed about the considerations 
prior to delivery, since patients preference has to be taken into account. Timing of delivery 
is individualized, according to the cardiac and obstetric status of the mother and fetal well 
being. In patients with heart failure delivery at 34 weeks can be considered to allow early 
optimisation of treatment modalities for the mother. 
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The mode of delivery depends on the maternal hemodynamic situation and obstetric factors. 
Women with adequate cardiac output may tolerate induction of labour and vaginal 
delivery. Vaginal delivery can lead to fluctuations in blood pressure, especially in prolonged 
labour. Assisted vaginal delivery (by vacuum or forceps extraction) is recommended in 
some women to avoid excessive maternal efforts and prolonged labour. (Roth & Elkayam, 
2008) Adequate pain relief is very important, but epidural anaesthesia is contraindicated 
when the patient is on antithrombotic or anticoagulant treatment. 
During caesarean section blood pressure can be controlled, stress and pain can be relieved 
and a stable environment can be created. However, caesarean section has been associated 
with a higher risk of venous thrombo-embolism, infection and peripartum haemorrhage. In 
some cases general anaesthesia will be necessary with some risk of complication. (Deneux-
Tharax et al., 2006) In addition, blood loss during caesarean section has been shown to be 
greater than during vaginal delivery.  
5.5 Post partum period  
The volume shifts caused by auto-transfusion can be dangerous in patients with diminished 
left ventricular function. Close monitoring on a medium care unit may be advisable for the 
first 3 days after delivery. Early recognition of heart failure and immediate treatment with 
diuretics can be achieved by close monitoring of the patients and measurement of the 
central venous pressure. Some cardiologists advise prophylaxic diuretics in patients with 
severe systemic ventricular dysfunction. Ideally monitoring should be done in a unit with 
neonatal care, since early bonding of mother and child is very important. In patients with 
normal ventricular function after ACS prior to pregnancy close monitoring in-hospital for at 
least three days after delivery is advisable. The main risk during this period consists of 
thrombo-embolic events cause by the hypercoagulable state of pregnancy exacerbated by 
even higher tPA inhibitor levels immediately after delivery.  
5.6 Breast feeding  
The effects of breast feeding on maternal cardiovascular function are caused by circulating 
hormones. High levels of oxytocin circulate through the body. In the study of Mezzacappa 
cardiac output during breastfeeding was found to be higher than in bottle feeding mothers. 
They describe a decrease in heart rate and a slight increase in systolic blood pressure during 
the first minutes of breast feeding. (Mezzacappa et al., 2001) Light et al described a lower 
blood pressure in breast feeding mothers one hour after breast feeding. (Light et al., 2000) In 
the first weeks of breast feeding, women produce around 800 millilitres of milk daily. With 
the production of breast milk large volume shifts take place, these may cause a problem in 
patients with reduced left ventricular function.  
The fluctuations in blood pressure may be harmful in severely symptomatic patients and 
bottle feeding should be considered. Lactation is also associated with a risk of bacteraemia 
secondary to mastitis. 
6. Angina in the pregnant patient 
A 41 year old patient presented to the emergency department with acute chest pain. There was a 
myocardial infarction at young age in her family history. She was 18 weeks pregnant with her first 
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child. She did not take any alcohol or medication during pregnancy. But she was continuing smoking 
during pregnancy. She had a blood pressure of 135/85mmHg, a pulse of 95 beats per minute and 
auscultation of the chest revealed normal breath sounds without rales. The ECG was normal. 
Transthoracic echocardiography revealed no wall abnormalities. Troponine levels were normal. 
During exercise testing she performed 92% of expected and during testing a down sloping ST 
depression of 2-3 mm was found in lead II, III and aVf. 
6.1 Signs and symptoms  
Evaluating chest pain in pregnant women can be challenging, since chest pain in pregnancy 
is common and can be caused by various conditions. Most often chest pain is caused by 
gastro-oesophageal reflux which is benign in most cases. Chest pain should never be 
ignored as it may also represent possible life threatening disease such as pericarditis, 
myocarditis, aortic dissection, hypertensive crisis, pulmonary thrombo-embolism or acute 
coronary syndrome. Urgent complete cardiac review is always appropriate if a pregnant 
woman presents with chest pain. 
Physical examination can be misleading, hypotension and tachycardia are physiological 
responses to normal pregnancy (as describe in sub-chapter 3). In this case normal lung 
examination and oxygen saturation made pneumonic disease less likely, but pulmonary 
thrombo-embolism remained a possibility. Measuring blood pressure in both arms is 
important since aortic dissection is a part of the differential diagnosis. 
6.2 Diagnostic testing  
Criteria for ACS in pregnancy are the same as in non pregnant women, consisting of a 
combination of symptoms, ECG changes and positive cardiac markers. Normal diagnostic 
tests can be used in pregnancy, but outcome has to be evaluated against normal pregnancy 
values, since abnormal values can be normal in pregnancy. Table (2) gives a brief summary 
of the changes most often seen in diagnostic tests. 
 
Diagnostic test Effect of normal pregnancy 
Electrocardiogram Left axis deviation and Q waves in lead III and aVF, inverted T 
waves in lead III  
Exercise test Decreased exercise tolerance 
Echocardiogram Increase in left ventricular mass, mild mitral regurgitation 
Serum creatinine kinase Elevated during labour  
Troponin  Not affected during normal pregnancy 
Table 2. The changes in diagnostic tests in normal pregnancy.  
The electrocardiogram (ECG) changes as a result of the upward shift of the diaphragm with 
the growing uterus. A left axis deviation with Q waves in lead III and aVF is seen in the 
third trimester. T waves can be inverted in lead III, V1 and V2. In case of a caesarean section 
with general anaesthesia ST depression is seen often. (Prebitero et al., 2009) 
The use of echocardiography is safe in pregnancy because echocardiography does not 
involve radiation. Detection of wall motion abnormalities can be used as a sign of possible 
acute coronary syndrome. In normal patients exercise tests are used to confirm the diagnosis 
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of coronary artery disease or after ACS to establish exercise capacity and exclude residual 
ischemia. In pregnancy it is advisable to use submaximal exercise (<70% of the maximum 
predicted heart rate) testing, since fetal bradycardia and absence of body movement have 
been described after heavy maternal exercise. (Elkayam et al., 1998) There is no evidence of 
increased risk of spontaneous abortion after exercise testing.  
Biomarkers are used in the cardiological practice to confirm the diagnosis of acute coronary 
syndrome. During labour elevated creatinine kinase (CK) and CK MB are found due to 
uterine contractions. These levels normalize during the second day after labour. (Poh & Lee, 
2010) Troponine I is not elevated in normal pregnancy, as a result troponin I is the 
recommended biomarker in pregnancy. However, troponin I serum levels can be elevated in 
patients with pre-eclampsia and hypertensive crisis. It is not totally clear whether this is a 
sign of cardiac ischemia in these partients. 
Chest radiography is only used in pregnancy during emergency medical conditions. If 
proper shielding of the abdomen is used radiation of chest radiography is considered 
relatively safe (especially in the third trimester). (Hirshfeld et al., 2005)  
6.3 Treatment choices in patients with chest pain  
The choice of treatment is dependent on the diagnosis and the presence of ECG changes. In 
patients without any ECG changes, other causes of chest pain should be considered; 
troponin should be measured in all patients. In women with ACS, conservative treatment 
(bed)rest, nitrates and beta blockers is advised. In NSTEMI patients a careful assessment 
should be made. Troponin levels, hemodynamic state and relief of pain determine whether 
the patient should have a coronary angiogram. A coronary angiogram will reveal the origin 
of the problem, eg dissection, thrombus. But a conservative treatment may be best in the 
majority of patients. STEMI patients need immediate treatment and PCI as first choice 
treatment should be performed as soon as possible.  
In patients with angina catherization should be considered. If proper shielding of the 
abdomen is used, radiation dose is low. An interventional procedure may result in a fetal 
exposure of <1 rad. Termination of pregnancy is generally not recommended, although it 
may be considered when the fetal radiation dose exceeds 10 rad. (Roth & Elkayam, 2008) 
The patient became pain free after the use of nitroglycerine and was treated with beta blockade. 
Further pregnancy was uneventful and she delivered a healthy baby boy at 39 weeks after 
spontaneous vaginal delivery.  
7. Acute coronary syndrome during the first or second trimester of 
pregnancy 
A 38 year old patient came to the emergency department with acute chest pain. She was 25 weeks 
pregnant with her second child. The first pregnancy was complicated by preeclampsia. She has no 
dyspnoea, syncope, cough or fever. She did not smoke nor use any alcohol or medication during 
pregnancy. She had a blood pressure of 100/60mmHg, a pulse of 105 beats per minute and was 
tachypnoeic at 24 breath per minute. Oxygen saturation by pulse oximetry was 99%. Auscultation of 
the chest revealed normal breath sounds without rales. The heart sounds were normal, no murmur or 
gallop was heard. Abdominal examination did not reveal any abnormalities and there was no oedema. 
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The results of the ECG were consistent with STEMI of the anterior wall with ST elevation in V1-V3 
and ST depression in lead II, III and aVF. Transthoracic echocardiography revealed a dyskenetic left 
anterior wall. The patient underwent coronary angiography three hours after onset of complaints and 
revealed a thrombotic obstruction of the left main artery with TIMI flow grade 1.  
7.1 Cause of ACS 
ACS in pregnancy has other causes than in the non-pregnant state. In the review of Roth 
and Elkayam only 40% (41 of the 103 patients) was caused by coronary artery stenosis. (Roth 
& Elkayam, 2008) Other causes were thrombus in 8%, coronary artery dissection in 27%, 
vascular spasm in 2% and normal coronary arteries were found in 13% of the patients. (Roth 
& Elkayam, 2008) ACS has been noted to occur more often in the anterior wall. (Iadanzo et 
al., 2007) 
Coronary dissection is very rare in the non-pregnant population, but more frequently seen 
in pregnancy (27%) especially in patients with ACS in the peripartum period (50%). Excess 
of progesterone is thought to be one of the causes of coronary dissection, since it causes 
biochemical changes of collagen in the coronary vessel wall and weakens the media. The 
impact of increased blood volume and cardiac output may cause extra wall stress which is 
hypothesised to be an additional factor (Roth & Elkayam, 2008) also autoimmune conditions, 
such as systemic lupus erythromatosis and anti-phospolipid-antibody syndrome, have been 
linked to coronary artery dissection. (Nallamonthu et al., 2005) 
Normal coronary artery morphology is found in 13% of patients, perhaps caused by 
transient coronary spasm or thrombus. Vascular spasm was found in 2% of the case reports 
described by Roth. (Roth & Elkayam, 2008) Spasm might be caused by enhanced vascular 
reactivity to angiotensin II, norepinephrine and endothelial dysfunction. (Nisell et al., 1985) 
Vascular spasm in combination with the hypercoagulable state of pregnancy may cause 
coronary thrombus leading to acute coronary syndrome. Patients who continue to smoke 
during pregnancy have an increased risk of coronary artery thrombosis due to enhanced 
platelet aggregability in smokers.  
7.2 Treatment  
When tests have confirmed the diagnosis of acute coronary syndrome, it is important to 
make a treatment plan and inform the patient about maternal and fetal risks of all possible 
treatment options.  
There is only limited information available on PCI during pregnancy. Nowadays pregnancy 
is not a contraindication for PCI and since PCI is the primary treatment for non-pregnant 
STEMI patients, more and more cases of stenting during pregnancy are published. With PCI 
as a treatment modality during pregnancy mortality of ACS has dropped. James described 
PCI in 135 patients (of which 127 were with stenting), but no information on outcome was 
published. In the first review of Roth and Elkayam in 1996 only 3 of the 125 patients had 
PCI. (Roth & Elkayam, 1996) Whereas in their second review 38 patients had a PCI, all with 
bare metal stenting. In this review 92 patients had a coronary angiogram (of which 43 were 
postpartum). After PCI one patient needed CABG because of extensive coronary dissection. 
(Roth & Elkayam, 2008) 
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The preference for bare metal stenting is caused by the requirement of dual anti-platelet 
treatment around the delivery and the lack of experience. The use of drug eluting stents has 
been described in 2 case reports. One patient with STEMI at 27 weeks of gestation received a 
drug eluting stent, she delivered a healthy child by elective caesarean section at 35 weeks. 
Antiplatelet therapy was continued during delivery. However, post partum she had a 
haemoglobin drop of 5 g/dL and needed a blood transfusion. (Al-Aqeedi & Al-Nabti, 2008) 
Since pregnant women are excluded from most clinical trials no randomised controlled 
trials have been preformed on thrombolytic therapy, PCI or CABG in the pregnancy. 
However, thrombotic therapy is considered to be relatively contraindicated in patient with 
acute coronary syndrome because of bleeding complications. In stroke, pulmonary 
embolism and mechanical heart valve thrombosis there is some clinical experience with 
several strategies such as tPA, urokinase and streptokinase. This medication does not cross 
the utero-placental barrier. (Leohardt et al., 2006) Maternal and fetal outcomes were 
favourable, but complications, as maternal haemorrhage, fetal loss, abruption placenta, 
preterm delivery and post partum haemorrhage have been reported in up to 10% and 
maternal mortality was 1.2 %. (Turrentine et al., 1995) The risk of haemorrhage is highest in 
the peripartum period (Murugappan et al,. 2006) and given the high incidence of coronary 
dissection in pregnancy, the use of thrombolytic therapy could lead to haemorrhage and 
further progression of the dissection. Thrombolytic therapy should be considered in case of 
thrombosis and possibly when primary PCI is not available. ( Roth & Elkayam, 2008) 
Very limited data is available on coronary artery bypass grafting (CABG) during pregnancy, 
no conclusion on safety for the mother or the unborn child can be made. In normal non-
pregnant patients with ACS CABG is used when multiple vessels or the left main coronary 
artery are involved. (Nallamonthu et al., 2005) In the data by James 61 women underwent 
CABG, but there was no specific data on outcome in these patients. In the case study of Roth 
and Elkayam 10 patients were described who underwent CABG, of which were 7 due to 
coronary artery dissection, (Roth & Elkayam, 2008) in these cases one fetal death and one 
late maternal death were reported. (Garvey, 1998) Large differences in maternal mortality 
rates were found for ACS in pregnant women in the last decades, ranging from 5,1%(James 
et al., 2006) to 38%. (Koul et al., 2001) The decline in mortality rate could be explained by the 
detection of ACS in less severely ill patients as well as improvement in treatment options in 
the last decades. (Roth & Elkayam, 2008) 
7.3 Delivery 
Delivery should be postponed if possible for at least 2 or 3 weeks after the ACS to allow 
adequate healing. (Prebitero et al., 2009) Anti-platelet therapy should be continued in case of 
recent stent implantation, low dose aspirin is also advisable in patient with other forms of 
coronary artery disease, but doctors should be aware of a higher risk of post partum 
haemorrhage. Vaginal delivery with shortened second stage of labour and adequate pain 
relief can be safe. Caesarean section is the preferred mode of delivery in patients with 
cardiac instability. 
7.4 Post partum period  
Close monitoring on a medium care unit may be advisable for the first 3 days after delivery. 
With anticoagulant and anti-platelet therapy given during pregnancy, special attention 
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should be paid to major haemorrhage. Ideally monitoring should be done in a unit with 
neonatal monitoring. 
In our patient thrombosuction was performed and a bare metal stent was inserted. She was treated 
with heparin for 24 hours and received aspirin, beta blockade and nitrates during the remainder of the 
pregnancy. Clopidogrel was not given during pregnancy. She delivered 12 weeks later at 37 weeks by 
the assisted vaginal route. Epidural pain medication was given to limit pain and stress. A healthy girl 
(3045 gram) was born. After delivery she was treated with a statin and an ACE inhibitor.  
8. Acute coronary syndrome in the third trimester  
A 34 year old patient presented to the emergency department with acute chest pain. She was 36 weeks 
pregnant. The results of the ECG were consistent with acute myocardial infarction of the anterior 
wall. The patient underwent cardiac catheterisation two hours after onset of symptoms, coronary 
angiogram revealed a coronary artery dissection of the left anterior descending artery.  
8.1 ACS in the third trimester 
Coronary artery disease in the peripartum period differs from ACS in the antepartum 
period in terms of coronary abnormality, cause, treatment options and mortality rate. 
Coronary dissection was the primary cause of coronary artery disease in the peripartum 
period (50%) and more commonly in post-partum period (34%) compared to antepartum 
period (11%). This is probably the result of hormonal changes and the stress on the walls of 
the coronary arteries during labour. In some cases an association with the administration of 
the medicine terbutaline (a medicine used to stop early uterine contractions) was found.  
The mortality rate in patients with ACS in the peripartum period is 18% versus 9% in the 
antepartum and postpartum period. (Roth & Elkayam, 2008) This was also shown in the 
study of Ladner, who reprted a mortality rate of 19% in the peripartum period. No specific 
cause for the high maternal mortality in the peripartum period was given. Different causes 
for high mortality rates could be hypothesized. The symptoms could be misinterpreted 
during delivery and both patient delay as well as doctor delay could lead to late recognition 
of ACS. A second reason could be the complication and mortality rate is relatively higher in 
patients with coronary artery dissection compared to coronary arthrosclerosis. (Basso et al., 
1996) A third reason is that major haemorrhage may result from anti-thrombotic therapy. 
And finally, cardiac failure after delivery caused by autotransfusion with stressing the 
injured myocytes could lead to maternal death. Moran et al described myocardial ischemia 
in normal patients during elective caesarean section. By using Holter monitoring and 
analysis of troponin I he showed ischemic changes in 8% of the patients and 81% had ST 
segment changes. None of these patients needed any form of treatment. This study showed 
that even normal healthy women experience ECG changes which may reflect some 
myocardial ischemia during caesarean section. (Moran et al., 2001)  
8.2 Treatment in peripartum period  
Treatment options are limited in the peripartum period, since anticoagulation and 
antithrombotic therapy should be discontinued 24 hours prior to delivery to avoid major 
bleeding complications. PCI is the treatment of choice in patients with STEMI. As pregnant 
patients have a substantial higher chance of coronary dissection and a high maternal 
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mortality, PCI should be preformed in a larger referral centre with cardiothoracic surgery 
standby.  
8.3 Delivery and postpartum period 
Caesarean section prior to CAG is a possible strategy in patients with ACS diagnosed after 
32 to 34 weeks of gestation. (Hameed & Sklansky, 2007) At this point fetal outcome is 
generally good and maternal benefit is high because of reduced stress during the last weeks 
of pregnancy and the use of antithrombotic therapy after PCI. Close monitoring on a 
medium care unit may be advisable for the first 3 days after delivery.  
It is very important to consider ACS in peripartum patients with acute chest pain. Early recognition 
and diagnosis can save lives. A healthy baby girl was born at 39 weeks. The patient stayed in the 
hospital until 3 days after delivery. 
9. Acute coronary syndrome in the postpartum period 
After delivery of a healthy girl, a 31 year old patient was treated with bromocriptine to suppress 
lactation. Four days after delivery she presented to the emergency department with acute severe chest 
pain. The ECG showed an acute anterior myocardial infarction with ST elevation in V1-V3. 
Coronary angiography revealed a dissection of the left anterior descending artery and she was treated 
with bare metal stenting. She remained in the hospital for 3 more days and was treated with 
betacblockade, aspirin and clopidogrel.  
9.1 Post partum ACS  
Coronary dissection was found in 34% of the coronary angiograms and this was the most 
frequent cause of ACS in the postpartum period as it was in the peripartum period. 
Postpartum, some cases of ACS are associated with the administration of medicine. There 
are nineteen cases reported of ACS after the administration of bromocriptine, which is used 
to suppress lactation. Bromocriptine has dopaminergic agonist properties and may have 
vasopastic effects which can lead to thrombus formation. (Hopp et al., 1996) This medication 
has been taken off the market as a lactation suppressant because of these reports. The second 
medicine associated with ACS is ergotamine, which is commonly used to prevent post 
partum haemorrhage by stimulating uterine contractions. Ergot derivatives are known to 
reduce the capacity of the intravascular lumen by 15-20% in normal coronary arteries. Eight 
cases of postpartum myocardial infarction have been described. (Eom, 2005) It is important 
to consider ACS as a possible complication before administration of this medicine in high 
risk patients (high age and cardiovascular risk factors).  
9.2 Treatment post partum ACS  
After delivery the treatment options are greater. Only maternal health determines the 
treatment, as is usual in “normal” cardiac patients PCI is the treatment of choice. Drug 
eluting stents can be used now. However, the uterine vascular bed has to be considered a 
large wound until one week after delivery.  
Bromocriptin, ergotamine and terbutaline have been associated with post partum ACS.  
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10. Neonatal outcome  
Neonatal outcome is strongly correlated with maternal outcome. In the first report of Roth 
and Elkayam 16 fetal deaths in 125 pregnancies (13%) were reported, of which 10 (62%) 
associated with maternal death. (Roth & Elkayam, 1996) In the second report only a 9% fetal 
death rate was reported, of which two were elective terminations because of potential drug 
teratogenicity. (Roth & Elkayam, 2008) Ladner et al described low birth weight and 
prematurity in patients with antenatal ACS and a 10% fetal death rate was reported in 
patients with intrapartum ACS. (Ladner et al., 2005) 
Fetal mortality is high in cardiac surgery during pregnancy with rates as high as 30% (Parry 
& Westaby, 1996). Factors which predicted an adverse fetal outcome were severity of 
maternal illness, total operative time, emergency surgery, reoperation, advanced maternal 
age and gestational age. (Barth, 2009)  
During cardiopulmonary bypass, continuous fetal monitoring should be performed. The 
fetal heart rate can be used as an indicator of placental perfusion to guide bypass pump 
flow. (Chandrasekhar et al., 2009) Uterine monitoring is essential to allow early control of 
these contractions as they are associated with significant fetal loss. (Parry & Westaby, 1996) 
Deleterious effects on the fetus are thought to be related to hypotension, hypothermia, 
embolic complications and inadequate placental flow. Caesarean delivery prior to CABG or 
PCI can be considered from 28 weeks of gestation. (Barth, 2009)  
Fetal mortality in PCI compared to CABG is low. Proper shielding of the abdomen is 
essential in fetal protection. (Roth & Elkayam, 2008) Where chest radiography is considered 
relatively safe (especially in the third trimester). Cardiac catherization and intervention 
procedures may result higher fetal exposure with some chance of fetal abnormalities, 
especially when used in the first trimester. 
11. Conclusion 
Acute coronary syndrome in women of childbearing age is rare, but pregnancy has shown 
to increase the risk of ACS 3- to 4-fold. (James et al., 2006) The overall incidence of 
pregnancy related acute coronary syndrome was reported between 2.7 and 6.2 per 100,000 
deliveries and seems to have been increased in the last decade. Maternal age is one of the 
most important risk factor for ACS during pregnancy. Mortality rate has declined over the 
last decades from 19% in 1922-1994 to 5,1% in 2001-2002, probably as a result of 
improvement in treatment modalities.  
Evaluating chest pain in pregnant woman can be challenging, since chest pain in pregnancy 
is common and may be caused by benign as well as life threatening diseases. Physical 
examination and diagnostic tests can be misleading, since normal pregnancy changes the 
results of these tests. Coronary artery disease in pregnancy has different causes than seen in 
non-pregnant women, artherosclerosis is less frequently found, whereas thrombus, 
dissection, spasm and normal coronary arteries are more often reported. In table 3 an 
overview is given of the management and outcome in the different patient groups. 
Not all medication is safe during pregnancy, fetal and maternal risks have to be taken into 
account when medication is given. Pregnancy is not a contraindication for PCI anymore and 
this is probably the main reason maternal mortality has fallen recently. Very limited data is 
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Patient group Counselling First treatment 
choice 
Maternal 
outcome  
Fetal outcome 
Previous ACS Check medication Medication No data No data 
ACS and impaired 
LV function 
Risk stratification Medication No data, high 
risk 
No data 
ACS antepartum Not applicable PCI 9 % mortality 11 % mortality 
ACS peripartum Not applicable PCI  18 % mortality 5 % mortality 
ACS postpartum Not applicable PCI 9 % mortality No fetal 
mortality 
Table 3 Oversight of different patient groups in ACS in pregnancy.  
available on CABG during pregnancy, and it should only be considered when all other 
therapeutic options have failed. Neonatal outcome is strongly correlated with maternal 
outcome; reported mortality was highest in the peripartum period.  
The delivery should be planned by a multidisciplinary team consisting of an obstetrician, 
anaesthesiologist and cardiologist. Women with adequate cardiac output may tolerate 
induction of labour and vaginal delivery, but it is possible to create a potentially more stable 
environment during a caesarean section in high risk patients. Close monitoring in-hospital 
for at least one week after delivery is advised for patients with ACS in pregnancy. 
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